Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-10-24
2006-10-24
Campell, Bruce R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
07125844
ABSTRACT:
The present invention provides Dab9derivatives of amphomycin-type lipopeptide antibiotics that display antimicrobial activity against Gram-positive bacteria, methods and intermediates for synthesizing such compounds, and methods of using the compounds in a variety of contexts, including in the treatment and prevention of infections.
REFERENCES:
patent: 3057779 (1962-10-01), Shay et al.
patent: 3160561 (1964-12-01), Shibata et al.
patent: 3639582 (1972-02-01), Umezawa et al.
patent: 3781420 (1973-12-01), Nishimura et al.
patent: 3817973 (1974-06-01), Bouchaudon et al.
patent: 4524135 (1985-06-01), Abbott et al.
patent: 4977083 (1990-12-01), Boeck
patent: 4994270 (1991-02-01), Boeck et al.
patent: 5028590 (1991-07-01), Fukuda et al.
patent: 5039789 (1991-08-01), Fukuda et al.
patent: 5629288 (1997-05-01), Lattrell et al.
patent: 5912226 (1999-06-01), Baker et al.
patent: 6146872 (2000-11-01), Ueda et al.
patent: 6194383 (2001-02-01), Hammann et al.
patent: 6716962 (2004-04-01), Borders et al.
patent: 2002/0028771 (2002-03-01), Curran et al.
patent: 629636 (1998-12-01), None
patent: WO 99/43700 (1999-09-01), None
patent: WO 02/05837 (2002-01-01), None
Vertesy, et al “Friulimicins: Novel Lipopeptide Antibiotics with Peptidoglycan Synthesis Inhibiting Activity from Actinoplanes friulliensis sp. nov. II. Isolation and Structural Characterization,” The Journal of Antibiotics 53(8): 816-827, Aug. 2000.
Bodanszky, M. et al., “Structure of the Peptide Antibiotic Amphomycin,”Journal of the American Chemical Society 95(7): 2352-2357, Apr. 4, 1973.
Boeck, L.D. et al., “Deacylation of A21978C, an Acidic Lipopeptide Antibiotic Complex, ByActinoplanes utahensis,” The Journal of Antibiotics 41(8): 1085-1092, Aug. 1988.
Debono, M. et al., “Enzymatic and Chemical Modifications of Lipopeptide Antibiotic A21978C: The Synthesis and Evaluation of Daptomycim (LY146032),”The Journal of Antibiotics 41(8): 1093-1105, Aug. 1988.
Fujino, M., “On Glumamycin, a New Antibiotic. VI. An Approach to the Amino Acid Sequence,”Bulletin of the Chemical Society of Japan 38(4): 517-522, 1965.
Hausmann, W.K. et al., “Structure Determination of Fatty Acids from the Antibiotic Aspartocin,” inAntimicrobial Agents and Chemotherapy—1963, Proceeding of the Third Interscience Conference on Antimicrobial Agents and Chemotherapy, Sylvester, J.C. (ed.), American Society for Microbiology, 1963, pp. 352-359.
Hausmann, W.K. et al., “α, β-Diaminobutyric Acid Obtained from Aspartocin,”The Journal of Antibiotics 22(5): 207-210, May 1969.
Heinemann, B. et al., “Amphomycin, A New Antibiotic,”Antibiotics and Chemotherapy 3:1239-1242, 1953.
Hinuma, Y., “Zaomycin, A New Antibiotic from aStreptomycessp.,”The Journal of Antibiotics, Ser. A 7(4): 134-136, Aug. 1954.
Huber, F.M. et al., “The formation of daptomycin by supplying decanoic acid toStrptomyces roseosporuscultures producing the antibiotice complex A21978C,”Journal of Biotechnology 7(4): 283-292, 1988.
Martin and Hausmann, “Isolation and Identification of D-α-Pepecolic Acid, α[L],β-Methylaspartic Acid and α,β-Diaminobutyric Acid from the Polypeptide Antibiotic Aspartocin,”Journal of the American Chemical Society 82: 2079, Apr. 20, 1960.
Naganawa, H. et al., “A Novel Fatty Acid from Laspartomycin,”The Journal of Antibiotics 23(8): 423-424, Aug. 1970.
Naganawa, H. et al., “Laspartomycin, A New Anti-Staphylococcal Peptide,”The Journal of Antibiotics 21(1): 55-62, Jan. 1968.
Shay, A.J. et al., “Aspartocin. I. Production, Isolation, and Characteristics,”Antibiotics Annual 1959-1960,pp. 194-198.
Shoji, J-I et al., “Studies on Tsushimycin. I. Isolation and Characterization of an acidic acylpeptide containing a new fatty acid,”The Journal of Antibiotics 21(7): 439-443, Jul. 1968.
Vértesy, L. et al., “Friulimicins: Novel Lipopeptide Antibiotics with Peptidoglycan Synthesis Inhibiting Activity fromActinoplanes friuliensissp. nov. II. Isolation and Structural Characterization,”The Journal of Antibiotics 53(8): 816-827, Aug. 2000.
Boyd Vincent A.
Cameron Dale R.
Fardis Maria
Campell Bruce R.
Darby & Darby PC
Heard Thomas S.
Migenix Inc.
LandOfFree
Dab 9 derivatives of lipopeptide antibiotics and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Dab 9 derivatives of lipopeptide antibiotics and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Dab 9 derivatives of lipopeptide antibiotics and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3669954